SCHEMBL27218694

SCHEMBL27218694

Oc1cc(C(F)(F)F)nc(SCCCc2nc(-c3ccccc3)no2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.49
▸ HDAC2 Q92769 4/20 0.49
▸ HDAC8 Q9BY41 3/20 0.49
▸ LMNA P02545 3/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ L3MBTL1 Q9Y468 5/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SIRT2 Q8IXJ6 1/20 0.43
▸ NOTUM Q6P988 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218893 0.90 S1PR1 (0.47) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL27218812 0.90 SIRT2 (0.52) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL31494429 0.90 ALDH1A1 (0.47) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL27218682 0.84 S1PR1 (0.45) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL27218707 0.83 SMN1; SMN2 (0.48) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL27218848 0.80 SIRT2 (0.52) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL27218692 0.76 NOTUM (0.43) HDAC1HDAC2HDAC8LMNAMAPT
SCHEMBL29808217 0.74 L3MBTL1 (0.47) HDAC1HDAC2HDAC8LMNAMAPT
SCHEMBL27218808 0.74 RAB9A (0.50) HDAC1HDAC2HDAC8LMNATP53
SCHEMBL31494416 0.73 RAB9A (0.54) HDAC1HDAC2HDAC8LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 HDAC1 1242/4885HDAC2 1716/4885HDAC8 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback